MedTrace Logo

MSC Administration for the Management of Type 1 Diabetic Patients

NCT02893306 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2016-09-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether the administration of multipotent stromal cell also referred as to mesenchymal stem cells (MSCs), modified Type 1 Diabetes progression.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

BIOLOGICAL

MSCs

origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single

Sponsors & Collaborators

  • Clinica Alemana de Santiago

    collaborator OTHER

  • Universidad del Desarrollo

    lead OTHER

Principal Investigators

  • Paulette Conget, PhD · Universidad del Desarrollo

  • Claudio Mizon, MD · Clinica Alemana de Santiago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-31
Primary Completion
2017-03-31
Completion
2017-03-31

Countries

  • Chile

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02893306 on ClinicalTrials.gov